A citation-based method for searching scientific literature

Hélène Vanacker, Clémence Romeo, Isabelle Ray-Coquard. Curr Opin Oncol 2019
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
J L Meisel, D M Hyman, K Garg, Q Zhou, F Dao, M Bisogna, J Gao, N D Schultz, R N Grisham, M Phillips,[...]. Ann Oncol 2014
24
50

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Andrea Mafficini, Michele Simbolo, Alice Parisi, Borislav Rusev, Claudio Luchini, Ivana Cataldo, Elena Piazzola, Nicola Sperandio, Giona Turri, Massimo Franchi,[...]. Oncotarget 2016
49
50

Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
340
50


BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.
M Thrall, H H Gallion, R Kryscio, M Kapali, D K Armstrong, Julie A DeLoia. Int J Gynecol Cancer 2006
61
50

Germline mutations in Thai patients with nonmucinous epithelial ovarian cancer.
Tarinee Manchana, Prasit Phowthongkum, Chinachote Teerapakpinyo. World J Clin Oncol 2019
3
50

The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Mette Hjortkjær, Marianne Waldstrøm, Anders Jakobsen, Hanne Kanstrup, Erik Søgaard-Andersen, Karina Dahl Steffensen. Int J Gynecol Pathol 2017
18
50

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
M Moschetta, A George, S B Kaye, S Banerjee. Ann Oncol 2016
90
50

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, Siegal Sadetzki, Susan J Ramus, Beth Y Karlan, Diether Lambrechts, Evelyn Despierre, Daniel Barrowdale, Lesley McGuffog,[...]. JAMA 2012
366
50

BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Karuna Garg, Douglas A Levine, Narciso Olvera, Fanny Dao, Maria Bisogna, Angeles Alvarez Secord, Andrew Berchuck, Ethan Cerami, Nikolaus Schultz, Robert A Soslow. Am J Surg Pathol 2013
37
50

Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients.
Fátima H Vaz, Patrícia M Machado, Rita D Brandão, Cátia T Laranjeira, Joana S Eugénio, Aires H Fernandes, Saudade P André. J Histochem Cytochem 2007
16
50

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
Judith E Carser, Jennifer E Quinn, Caroline O Michie, Eamonn J O'Brien, W Glenn McCluggage, Perry Maxwell, Elisabeth Lamers, Tong F Lioe, Alistair R W Williams, Richard D Kennedy,[...]. Gynecol Oncol 2011
52
50

Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Marieke Arts-de Jong, Geertruida H de Bock, Christi J van Asperen, Marian J E Mourits, Joanne A de Hullu, C Marleen Kets. Eur J Cancer 2016
38
50

Identification of BRCA1-deficient ovarian cancers.
Anne-Bine Skytte, Marianne Waldstrøm, Anders Aamann Rasmussen, Dorthe Crüger, Emma R Woodward, Steen Kølvraa. Acta Obstet Gynecol Scand 2011
13
50

BRCA mutation in high grade epithelial ovarian cancers.
Tarinee Manchana, Natacha Phoolcharoen, Patou Tantbirojn. Gynecol Oncol Rep 2019
15
50

Homologous recombination deficiency and ovarian cancer.
Jonathan A Ledermann, Yvette Drew, Rebecca S Kristeleit. Eur J Cancer 2016
95
50

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
J L Lesnock, K M Darcy, C Tian, J A Deloia, M M Thrall, C Zahn, D K Armstrong, M J Birrer, T C Krivak. Br J Cancer 2013
87
50

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
J I Weberpals, D Tu, J A Squire, M S Amin, S Islam, L B Pelletier, A M O'Brien, P J Hoskins, E A Eisenhauer. Ann Oncol 2011
33
50

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
348
50

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Sonja J Gill, Jon Travers, Irina Pshenichnaya, Fiona A Kogera, Syd Barthorpe, Tatiana Mironenko, Laura Richardson, Cyril H Benes, Michael R Stratton, Ultan McDermott,[...]. PLoS One 2015
44
50

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Erika J Lampert, Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R Nair, Yingmiao Liu, Elizabeth M Swisher, James W Hodge, Andrew B Nixon, Erin Nichols,[...]. Clin Cancer Res 2020
33
50

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
876
50

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa L Werner, Bente Lund, Gabriel Lindahl,[...]. Lancet Oncol 2019
68
50

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed Ashour Ahmed, Dariush Etemadmoghadam, Jillian Temple, Andy G Lynch, Mohamed Riad, Raghwa Sharma, Colin Stewart, Sian Fereday, Carlos Caldas, Anna Defazio,[...]. J Pathol 2010
439
50

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
50

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.
S Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, Domenico Ferraioli, Olfa Derbel, Alexandre Bodmer, Patrick Petignat, Beata Rak, Nicolas Chopin, Olivier Tredan,[...]. Clin Cancer Res 2018
21
50

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
141
50

Structural basis for allosteric PARP-1 retention on DNA breaks.
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A Hancock, Jamin D Steffen, Ramya Billur, Zain M Hannan, Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt,[...]. Science 2020
58
50

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Lucy C Riches, Antonio G Trinidad, Gareth Hughes, Gemma N Jones, Adina M Hughes, Andrew G Thomason, Paul Gavine, Andy Cui, Stephanie Ling, Jonathan Stott,[...]. Mol Cancer Ther 2020
29
50

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, David Scott Miller, Noelle Cloven, Gini F Fleming, Andrea E Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M Oza,[...]. Lancet Oncol 2019
142
50

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
69
50

Pan-cancer landscape of homologous recombination deficiency.
Luan Nguyen, John W M Martens, Arne Van Hoeck, Edwin Cuppen. Nat Commun 2020
34
50

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, Michael Birrer, Jung-Min Lee, Ronald J Buckanovich, Gini F Fleming, Bj Rimel, Mary K Buss, Sreenivasa Nattam, Jean Hurteau,[...]. Lancet Oncol 2014
356
50

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. J Clin Oncol 2020
10
50

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Stephen T Durant, Li Zheng, Yingchun Wang, Kan Chen, Lingli Zhang, Tianwei Zhang, Zhenfan Yang, Lucy Riches, Antonio G Trinidad, Jacqueline H L Fok,[...]. Sci Adv 2018
73
50

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
165
50

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
50

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
767
50

Tumour lineage shapes BRCA-mediated phenotypes.
Philip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, Preethi Srinivasan, Shweta S Chavan, Noah D Friedman, Ezra Y Rosen, Allison L Richards, Nancy Bouvier, S Duygu Selcuklu,[...]. Nature 2019
119
50

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
50

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
554
50

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
Ainhoa Madariaga, Valerie Bowering, Soha Ahrari, Amit M Oza, Stephanie Lheureux. Int J Gynecol Cancer 2020
7
50

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Triparna Sen, B Leticia Rodriguez, Limo Chen, Carminia M Della Corte, Naoto Morikawa, Junya Fujimoto, Sandra Cristea, Thuyen Nguyen, Lixia Diao, Lerong Li,[...]. Cancer Discov 2019
213
50

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Alex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, Aurélie Ayme, Solène De Talhouet, Jean-Damien Combes, Julien Peron, Alexandre Bodmer, Sophie Giraud, Adrien Buisson,[...]. Breast Cancer Res Treat 2019
7
50

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Roman M Chabanon, Gareth Muirhead, Dragomir B Krastev, Julien Adam, Daphné Morel, Marlène Garrido, Andrew Lamb, Clémence Hénon, Nicolas Dorvault, Mathieu Rouanne,[...]. J Clin Invest 2019
110
50

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Jung-Min Lee, Jayakumar Nair, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Maria J Merino, Elizabeth M Swisher, Maria I Harrell, Jane B Trepel, Min-Jung Lee,[...]. Lancet Oncol 2018
80
50

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
602
50

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog,[...]. J Clin Oncol 2020
85
50

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.